abstract |
The present invention provides an antibody against X3CR1 and uses of fractalkine. The anti-CX3CR1 antibody facilitates identification, removal and separation of killer lymphocytes. Further, by suppressing the interaction between CX3CR1 and fractalkine, it is possible to provide an antibody drug that suppresses killer lymphocyte migration and suppresses cytotoxic activity. [Selection figure] None |